XML 15 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 15,853,236 $ 23,693,633
Short-term investments 77,945,753 57,538,852
Accounts receivable 776,295 3,316,361
Accounts receivable from affiliated entities 978,544 738,583
Prepaid expenses and other current assets 1,677,602 1,406,590
Prepaid expenses and other current assets from affiliated entities 1,581,111 1,120,805
Total current assets 98,812,541 87,814,824
Fixed assets, net 13,516,389 15,949,014
Intangible assets, net 3,960,457 4,760,145
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 14,002,860  
Other assets 2,731,055 2,669,998
Total assets 151,533,430 131,113,265
Current liabilities:    
Accounts payable and accrued expenses 9,783,964 23,134,733
Accounts payable and accrued expenses due to affiliated entities 462,596 977,792
Accrued clinical trial expenses 4,500,898 5,671,764
Deferred revenue 106,111 223,577
Deferred revenue from affiliated entities 64,825 33,575
Deferred rent   1,065,387
Operating lease liability 2,011,008  
Deferred grant funding 1,896,526 4,165,848
Deferred grant funding from affiliated entities 720,925 27,083
Total current liabilities 19,546,853 35,299,759
Deferred revenue, net of current portion 124,105 150,793
Derivative liability 4,503,918 0
Deferred rent, net of current portion   8,518,207
Operating lease liability, net of current portion 20,953,308  
Deferred tax liabilities 26,649 24,766
Deferred grant funding from affiliated entities 135,000 0
Other liabilities 50,343 87,333
Total liabilities 115,414,698 44,080,858
Stockholders’ equity:    
Preferred stock 0 0
Common stock 99,046 97,226
Additional paid-in capital 735,017,743 707,794,215
Accumulated deficit (702,123,617) (620,426,436)
Accumulated other comprehensive income (loss) 700,398 (528,867)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 33,693,570 86,936,138
Non-controlling interest 2,425,162 96,269
Total stockholders’ equity 36,118,732 87,032,407
Total liabilities and stockholders’ equity 151,533,430 131,113,265
GeneOne Life Sciences    
Current assets:    
Investment in affiliated entity 5,707,256 6,381,926
Other assets 338,000 381,000
Plumbline Life Sciences    
Current assets:    
Investment in affiliated entity 2,289,501 3,023,987
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 62,119,671 0
Korean Won Convertible Bonds Due 2024    
Current liabilities:    
Convertible debt $ 7,954,851 $ 0